Exagen Inc. (XGN) income statement
XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.90+0.14 (+3.72%)
Close on Nov 18, 2026Market cap $94.48MP/E –Yield –
Exagen Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 58.6%
- Operating margin
- -18.6%
- Net margin
- -26.6%
- Return on equity, FY2025
- -147.8%
Financial strength
- Current ratio
- 3.18
- Debt to equity
- 1.87
- Debt to assets
- 44.0%
- Cash to current liabilities
- 182.7%
Valuation
- P/E ratio
- –
- Price to sales
- 1.33
- Price to book
- 7.73
- Dividend yield
- –
See a number that looks wrong?